Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.

Richard P. Junghans, Clark L. Anderson · Proceedings of the National Academy of Sciences · 1996 · 676 citations

Life Sciences, Biochemistry, Immunology +14

Myasthenia gravis activities of daily living profile

Gil I. Wolfe, Laura Herbelin, Sharon Nations et al. · Neurology · 1999 · 544 citations

Medicine, Pharmacology, Pharmacotherapy +16

Guidelines for treatment of autoimmune neuromuscular transmission disorders

Geir Skeie, Slobodan Apostolski, Amelia Evoli et al. · European Journal of Neurology · 2010 · 508 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice

Victor Gheţie, James G. Hubbard, Jin‐Kyoo Kim et al. · European Journal of Immunology · 1996 · 465 citations · Full text

Life Sciences, Immunology, Molecular Biology +16